Xencor Inc (XNCR): Net Income
-$91.92M
Year ended 2025-12-31
-$163.32M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$91.92M | n/m | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | -$232.62M | n/m | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | -$133.13M | n/m | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | -$55.18M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $82.63M | n/m | 2025-02-24, From 2021-01-01 |
| 2020-12-31 | -$69.33M | n/m | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $26.88M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | -$70.41M | n/m | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | -$38.49M | n/m | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $45.12M | n/c | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | -$17.59M | n/m | 2018-02-28, From 2015-01-01 |
| 2014-12-31 | -$16.42M | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | -$60.26M | n/a | 2016-03-08, From 2013-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Xencor Inc (XNCR) | 2025-12-31 | -$91.92M | n/m |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | -$38.72M | n/m |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $9.88M | -44.8% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | -$153.49M | n/m |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | -$196.04M | n/m |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $83.23M | n/m |
| Zymeworks Inc. (ZYME) | 2025-12-31 | -$81.13M | n/m |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $44.87M | n/m |
| Macrogenics Inc (MGNX) | 2025-12-31 | -$74.62M | n/m |
Compare XNCR, LFCR, GYRE, URGN side by side · Screen every company in Pharmaceutical Preparations ↗